A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Canagliflozin/metformin (Primary) ; Canagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 30 Jun 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 02 Apr 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
- 04 Mar 2014 New trial record